You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Twitter Demographics
Mendeley readers
Attention Score in Context
| Title |
Governance and pharmacovigilance in Brazil: a scoping review
|
|---|---|
| Published in |
Journal of Pharmaceutical Policy and Practice, February 2016
|
| DOI | 10.1186/s40545-016-0053-y |
| Pubmed ID | |
| Authors |
Kathy Moscou, Jillian C. Kohler, Anita MaGahan |
| Abstract |
This scoping review investigates the relationship between governance, pharmacovigilance, and Agencia Nacional de Vigilancia Sanitaria (ANVISA) in Brazil, which has authority over Brazil's national pharmaceutical policy, drug registration and coordination of the national pharmacovigilance system. The purpose is to investigate opportunities for effective pharmacovigilance. Sixty-three terms pertaining to pharmacovigilance in Brazil and ANVISA, global institutions, pharmaceutical industry, and civil society were searched in thirteen relevant databases on November 17-18, 2013. Using a pharmacogovernance framework we analyzed ANVISA's pharmacogovernance: the manner in which governing structures, policy instruments, and institutional authority are managed to promote societal interests for patient safety due to medication use. The integration of transnational policy ideas for regulatory governance into pharmacogovernance in Brazil was also investigated. Brazil's policy, laws, and regulations support ANVISA's authority to ensure access to safe medicines and health products however ANVISA's broad mandate and gaps in pharmacogovernance account for regional disparities in monitoring and assessing drug safety. Gaps in pharmacogovernance include: equity and inclusiveness; stakeholder coordination; effectiveness and efficiency; responsiveness; and intelligence and information. Pharmacogovernance that addresses 1) regional resource disparities, 2) federal and state lack of coordination of pharmacovigilance regulations, 3) asymmetric representation in the pharmaceutical regulatory agenda and which 4) disaggregates regulatory authority over health and commercial sectors would strengthen pharmacovigilance in Brazil. |
Twitter Demographics
The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 75% |
| United Kingdom | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Brazil | 1 | 1% |
| Unknown | 92 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 19 | 20% |
| Student > Bachelor | 10 | 11% |
| Researcher | 9 | 9% |
| Student > Doctoral Student | 8 | 8% |
| Student > Ph. D. Student | 7 | 7% |
| Other | 18 | 19% |
| Unknown | 24 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 24 | 25% |
| Medicine and Dentistry | 14 | 15% |
| Nursing and Health Professions | 8 | 8% |
| Biochemistry, Genetics and Molecular Biology | 5 | 5% |
| Business, Management and Accounting | 3 | 3% |
| Other | 16 | 17% |
| Unknown | 25 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 April 2016.
All research outputs
#12,944,099
of 22,844,985 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#206
of 407 outputs
Outputs of similar age
#182,272
of 398,933 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#5
of 7 outputs
Altmetric has tracked 22,844,985 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 407 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.2. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 398,933 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.